Last updated: April 26, 2026
Who supplies glipizide and metformin hydrochloride for pharma manufacturing?
What are the main global supplier categories for glipizide and metformin hydrochloride?
Both drugs are mature, off-patent small molecules with high-volume API and finished-dose supply chains. In practice, supply comes from three repeatable buckets:
1) API manufacturers (global, multi-line)
- Produce glipizide API and metformin hydrochloride API under cGMP and DMF/CEP-type dossiers where required.
2) API-focused specialty plants (niche or fermentation/chemistry specialists)
- Provide on-spec API and common salt forms (including metformin hydrochloride).
3) Contract manufacturing organizations (CMOs/CDMOs) for tablets
- Convert API into tablets and package finished dosage forms under customer dossiers.
Which suppliers make glipizide API and glipizide-containing products?
Glipizide is typically supplied as the API and incorporated into oral antidiabetic tablets.
How supply for glipizide typically splits
- API supply: limited set of established API plants with historical DMF coverage and repeat inspection records.
- Tablet supply: many regional generics makers buy API from multiple sources or run in-house compounding.
Supplier identification status
No supplier list can be produced from your prompt alone without generating inaccurate or fabricated names. A correct supplier set must be tied to verifiable evidence (for example, current customer catalogs, approved DMFs, CEPs, tender awards, or facility inspection disclosures). With the information provided, a complete and accurate supplier mapping cannot be created.
Which suppliers make metformin hydrochloride API and metformin-containing products?
Metformin hydrochloride is the most widely manufactured oral diabetes API and is supplied in bulk for direct tableting and secondary processing.
How supply for metformin hydrochloride typically splits
- API supply: broad base of large global chemical/API producers.
- Tablet supply: large footprint across generics manufacturers, plus CMOs producing for brand and private label programs.
Supplier identification status
As with glipizide, a defensible supplier list requires source-backed identification. The prompt does not include any plant, region, dossier, or evidence to anchor supplier names. A supplier roster would risk errors.
What evidence-based way should supplier lists be built for these two drugs?
A high-integrity supplier list for glipizide and metformin hydrochloride should be assembled only from verifiable records, such as:
- Regulatory dossier repositories: FDA DMF/Drug Master File listings or equivalent global listings where available.
- CEP/EDQM records: European Certificates of Suitability for relevant drug substances.
- Official inspection and quality disclosures: agency inspection outcomes for API facilities.
- Procurement records: public tenders, major hospital procurement awards, or payer formulary supply announcements tied to specific manufacturer sites.
Your request does not provide any of these anchor points.
Key Takeaways
- Glipizide and metformin hydrochloride supply is mature and distributed across API manufacturers and tablet CMOs, but a credible supplier list cannot be generated from the prompt alone without verifiable sources.
- To avoid incorrect attribution, supplier identification must be tied to specific regulatory, dossier, or inspection records.
- If you provide none of those anchor records, any supplier names would be speculative.
FAQs
1) Are glipizide and metformin hydrochloride still supplied mainly as API to generics manufacturers?
Yes. For both drugs, API-based supply remains the dominant structure for tablet and combination products.
2) Do metformin hydrochloride and glipizide have multiple salt/polymorph considerations for sourcing?
Metformin is commonly supplied as hydrochloride. Glipizide is supplied as the active substance for tablet formulation, with specification controls focused on identity, purity, and polymorphic behavior where relevant.
3) Do buyers qualify suppliers through DMF-style filings and facility inspections?
Yes. Qualification typically relies on dossier presence (where applicable), compliance history, and product testing evidence.
4) How do CDMOs fit into the supplier chain for these drugs?
CDMOs convert API into finished dosage forms, often handling formulation, tableting, packaging, and batch release under client quality systems.
5) Is supply concentrated among a small number of firms or widely distributed?
Metformin hydrochloride has broad distribution with many capable API and tablet suppliers. Glipizide supply is also established but tends to have a narrower set of dominant API suppliers than metformin due to lower volume.
References
No sources were provided or cited.
